参考文献/References:
[1] 骆雷鸣,任金霞.高血压心脏形态、结构改变及危害[J].中华保健医学杂志,2021,23(6):555-560.
LUO L M,REN J X.Hypertensive cardiac morphology,structural changes and hazards[J].Chin J Health Care Med,2021,23(6):555-560.
[2] 崔伟锋,刘萧萧,韩静旖,等.原发性高血压病心血管风险因素分析[J].中国全科医学,2020,23(22):2797-2803.
CUI W F,LIU X X,HAN J Y,et al.The risk factors of cardiovascular disease in patients with essential hypertension[J].Chin Gener Pract,2020,23(22):2797-2803.
[3] MA S,MENG Z,CHEN R,et al.The Hippo pathway:biology and pathophysiology[J].Annu Rev Biochem,2019,88:577-604.
[4] 顾燕妮,谢春毅.Hippo信号通路与心脏病[J].国际心血管病杂志,2021,48(5):281-284.
GU Y N,XIE C Y.Hippo signaling pathway and heart disease[J].Int J Cardiovasc Dis,2021,48(5):281-284.
[5] 王永煜,余薇,周斌.Hippo信号通路与心血管发育及疾病调控[J].遗传,2017,39(7):576-587.
WANG Y Y,YU W,ZHOU B.Hippo signaling pathway in cardiovascular development and diseases[J].Hereditas,2017,39(7):576-587.
[6] ZHENG A,CHEN Q,ZHANG L.The Hippo-YAP pathway in various cardiovascular diseases:focusing on the inflammatory response[J].Front Immunol,2022,13:971416.
[7] TE RIET L,VAN ESCH J H,ROKS A J,et al.Hypertension:renin-angiotensin-aldosterone system alterations[J].Circ Res,2015,116(6):960-975.
[8] VIGNESWARAN K,BOYD N H,OH S Y,et al.YAP/TAZ transcriptional coactivators create therapeutic vulnerability to verteporfin in EGFR-mutant glioblastoma[J].Clin Cancer Res,2021,27(5):1553-1569.
[9] 卓坤萍,姚阳,周明生,等.TAZ蛋白在血管紧张素Ⅱ诱导的人脐静脉内皮细胞MCP-1表达中的作用研究[J].中国继续医学教育,2022,14(17):190-194.
ZHUO K P,YAO Y,ZHOU M S,et al.The role of TAZ in angiotensin Ⅱ-induced MCP-1 expression in human umbilical vein endothelial cells[J].Chin Contin Med Edu,2022,14(17):190-194.
[10] GUZIK T J,TOUYZ R M.Oxidative stress,inflammation,and vascular aging in hypertension[J].Hypertension,2017,70(4):660-667.
[11] 张玉,马亮亮,张海垠.动脉粥样硬化性心血管疾病与H型高血压的关系研究[J].中国医药,2018,13(11):1620-1623.
ZHANG Y,MA L L,ZHANG H Y.Relationship between atherosclerotic cardiovascular disease and H-type hypertension[J].Chin Med,2018,13(11):1620-1623.
[12] LOW E L,BAKER A H,BRADSHAW A C.TGFβ,smooth muscle cells and coronary artery disease:a review[J].Cell Signal,2019,53:90-101.
[13] PETRIE J R,GUZIK T J,TOUYZ R M.Diabetes,hypertension,and cardiovascular disease:clinical insights and vascular mechanisms[J].Can J Cardiol,2018,34(5):575-584.
[14] POASAKATE A,MANEESAI P,POTUE P,et al.Genistein alleviates renin-angiotensin system mediated vascular and kidney alterations in renovascular hypertensive rats[J].Biomed Pharmacother,2022,146:112601.
[15] CHOUDHARY R,SHREE J,SINGH A,et al.Role of the reni-nangiotensin system in the development of cataract formation in angiotensin-Ⅱ-induced experimental rats[J].J Biochem Mol Toxicol,2021,35(7):e22789.
[16] EGUCHI S,DEMPSEY P J,FRANK G D,et al.Activation of MAPKs by angiotensin Ⅱ in vascular smooth muscle cells.Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK[J].J Biol Chem,2001,276(11):7957-7962.
[17] CAO X,LUO T,LUO X,et al.Resveratrol prevents Ang Ⅱ-induced hypertension via AMPK activation and RhoA/ROCK suppression in mice[J].Hypertens Res,2014,37(9):803-810.
[18] GUO R W,YANG L X,WANG H,et al.Angiotensin II induces matrix metalloproteinase-9 expression via a nuclear factor-kappaB-dependent pathway in vascular smooth muscle cells[J].Regul Pept,2008,147(1-3):37-44.
[19] POJER J M,MANNING S A,KROEGER B,et al.The Hippo pathway uses different machinery to control cell fate and organ size[J].iScience,2021,24(8):102830.
[20] NOGUCHI S,SAITO A,NAGASE T.YAP/TAZ signaling as a molecular link between fibrosis and cancer[J].Int J Mol Sci,2018,19(11):3674.
[21] 李晶晶.Hippo信号通路与皮肤组织细胞修复研究进展[J].中国美容医学,2020,29(1):162-165.
LI J J.Advances of Hippo signaling pathway and skin tissue cell repair[J].Chin J Aesth Med,2020,29(1):162-165.
[22] WANG L,LUO J Y,LI B,et al.Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow[J].Nature,2016,540(7634):579-582.
[23] PICCOLO S,DUPONT S,CORDENONSI M.The biology of YAP/TAZ:hippo signaling and beyond[J].Physiol Rev,2014,94(4):1287-1312.
[24] WENNMANN D O,VOLLENBROKER B,ECKART A K,et al.The Hippo pathway is controlled by angiotensin Ⅱ signaling and its reactivation induces apoptosis in podocytes[J].Cell Death Dis,2014,5(11):e1519.
[25] DUPONT S,MORSUT L,ARAGONA M,et al.Role of YAP/TAZ in mechanotransduction[J].Nature,2011,474(7350):179-183.